Xtampza ER, Collegium’s lead product candidate, is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is being developed for the management of pain severe enough to require
In addition, Knight has entered into an exclusive distribution agreement with Ember, a cutting-edge U.S.-based biopharmaceutical company, to commercialize its promising Bone Morphogenetic Protein-7 ("BMP-7") pipeline in Canada
"Hydropothecary is now one of a few licensed producers able to make new, ingestible product lines. The products will be available for purchase following rigorous safety testing and
As part of the transaction, iCardiac has also opened a new office in Longmont, Colorado to accommodate the project management, data management, customer support, IT, technology development and
As of July 15, 2015, the latest overall survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the HEAT Study patients),
PH1 is a severe, rare, inherited disorder of the liver that often results in kidney failure and for which there are no approved therapies. Orphan Drug Designation by
"ATryn, an innovative treatment for patients with hereditary antithrombin deficiency, marks Knight’s first submission to Health Canada", said Jonathan Ross Goodman, President and CEO of Knight. "ATryn is
The objective is to optimize Fc receptor mediated antibody function. The work will be conducted in the Laboratory of Molecular Genetics and Immunology at The Rockefeller University, which
IPF affects in the region of 100,000 people in the US. Current products are expected to produce global revenues in excess of $1.1 billion by 2017. The LOXL2
It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero. The launch of biosimilar Rituximab will provide a much needed access to patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.